Long-term outcomes and OS for zanidatamab + CTx in HER2+ mGEA: 4-year follow-up #ASCO25 🔎Phs-2 👉ORR 76 %m DoR 18.7 mo 👉mPFS 12.5 mo 👉mOS 36 mo 👉Manageable safety 👉95% concordance btw ctDNA & IHC 🧐 strong efficacy signal, phase-3 data awaited ESMO - Eur. Oncology

Funny how two of the more interesting pieces of data at #ASCO25 have little to do with extraneous medications per se, but rather the body’s circadian rhythm and physiology: 1: Exercise after surgery 2: Checkpoint inhibitors in the morning

Sub-typing to select NAT in #PDAC? NeoPancONE 🇨🇦 #ASCO25 Canadian Hepato-Pancreato-Biliary Association 👥84 resectable PDAC 💉mFOLFIRINOX NAT Median OS 34 months😀 🔬Classical vs basal sub-type main predictor EFS & OS What next🤔: sub-type all PDAC prior to chemo? wait for more data? ascopubs.org/doi/10.1200/JC…

🫁 Thrilled to have Dr. Rosalyn Juergens from Juravinski Research Institute with us as she shares key updates in lung cancer research and treatment. From biomarkers to breakthroughs—don’t miss this high-impact session! #LungCancer #ASCO25 OncologyEducation

Transforming the future of pancreatic cancer demands bold innovation, and that is precisely what Pancreatic Cancer North America is doing. NeoPancONE, a breakthrough study funded by our Canadian donors was highlighted at this year’s ASCO Conference. Read more: bit.ly/3FU2zlg #ASCO2025

🇨🇦 On stage now: Dr. Ronan McLaughlin, Dr. Stephen Chia and Dr. Elena Elimova spotlighting Canadian Achievements in Cancer Research — driving innovation, collaboration, and impact on global cancer care. Proud moment for 🇨🇦 oncology! #BOAT25 @ASCO25 #OncEd

This time of year is always the hardest! It has been my pleasure to work with this gang all year, who have been the most supportive colleagues one can dream of. The New York adventure begins! 🥰

Final COMPASS trial data advanced #PDAC ➡️268 WGS& 253RNA-seq ➡️basal-like& hi GRIm-S ⬇️OS, both unique TME inc CD8 variation,NB primaries vs mets ➡️LTS :HRD, KRAS WT ➡️KRAS major enriches basal, >type II DM ➡️LAPC≠intact SMAD4 ➡️47% receive 2nd line tx nature.com/articles/s4146…

The U of T Department of Surgery community mourns the loss of cherished colleague, Dr. Sean Cleary. "Sean has touched the lives of many of us – as a clinical colleague, teacher, mentor, supervisor, confidential advisor, and friend. . ." Read the Chair's message at surgery.utoronto.ca/news/Sean-Clea…

Ireland becoming 'world leader' in cancer research rte.ie/news/ireland/2… via RTÉ We are proud to support so much extraordinary Irish research and show the exceptional nurses and doctors caring for people with cancer . #cancerrevolution #freeexhibition

Huge privilege to be back stage with 🇮🇪 #WCLC25 Co-Chair Jarushka Naidoo during the opening plenary this afternoon in #Barcelona Jarushka - we’re fiercely proud of you representing #Irish Oncology on this global stage #IrishBackStage

Congrats Lawson Eng of University Health Network Princess Margaret Cancer Centre Princess Margaret Cancer Centre Research 🇨🇦 for being awarded the IASLC Lectureship in #TobaccoControlAndSmokingCessation 🚭. Super proud of what you have been working on and looking forward to your lecture! #LCSM #WCLC25

Our study found that, in early-stage lung cancer, smoking status can have a greater impact on survival outcomes than some traditional staging factors, led by our Clinician Investigator Dr. Lawson Eng and an international team of researchers. JTO & JTO CRR: jto.org/article/S1556-…

In pancreatic cancer, time is critical. A North American trial, led by our Dr. Jennifer Knox, shows that upfront molecular profiling may be key to seize the first-line treatment window, when the current options remain disappointing to patients. doi.org/10.1200/JCO-25…

Two important randomized trials in #PancreaticCancer published: 1st PASS-01 in metastatic cancer comparing FOLFIRINOX to Gem/Abraxane (Journal of Clinical Oncology) 2nd PREOPANC-2 in resectable/borderline resectable cancer comparing neoadjuvant FFX versus Gem/CRT (The Lancet Oncology) OncoAlert ⬇️

⚖️ mFOLFIRINOX vs Gem+nab-P in 1L PDAC - does the long-standing debate finally tilt one way? 🔑 Trial essentials (JCO 2025; PASS-01; randomized phase 2; n=160 ITT=140; NA multicenter; gBRCA/PALB2-WT): • 🧪 Arm A: mFOLFIRINOX • 💊 Arm B: Gemcitabine+nab-paclitaxel 📊 Key

🎉🎉🎉

🎉 And that’s a wrap! Thank you to all who joined us in celebrating 5 years of the AHOS Nursing Service! 💙Grateful to our presenters, to Miriam O Callaghan for her professional hosting, & to Minister Jennifer Carroll MacNeill for her inspiring words.

PASS-01: mFOLFIRINOX vs Gem/Nab-Pacli & Molecular Correlatives for #PDAC Journal of Clinical Oncology doi.org/10.1200/JCO-25… 👉Genomic data: 94%, transcriptomes: 74%, PDOs: 50% 👉OS/PFS similar btw GnP & mFFX 👉2nd line disappointing 👏impressive study, but precision medicine still with limited